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Abstract
Background: Impaired empathic abilities lead to severe negative social consequences and influence the development and 
treatment of several psychiatric disorders. Furthermore, empathy has been shown to play a crucial role in moral and prosocial 
behavior. Although the serotonin system has been implicated in modulating empathy and moral behavior, the relative 
contribution of the various serotonin receptor subtypes is still unknown.
Methods: We investigated the acute effect of psilocybin (0.215 mg/kg p.o.) in healthy human subjects on different facets of 
empathy and hypothetical moral decision-making using the multifaceted empathy test (n = 32) and the moral dilemma task 
(n = 24).
Results: Psilocybin significantly increased emotional, but not cognitive empathy compared with placebo, and the increase in 
implicit emotional empathy was significantly associated with psilocybin-induced changed meaning of percepts. In contrast, 
moral decision-making remained unaffected by psilocybin.
Conclusions: These findings provide first evidence that psilocybin has distinct effects on social cognition by enhancing 
emotional empathy but not moral behavior. Furthermore, together with previous findings, psilocybin appears to promote 
emotional empathy presumably via activation of serotonin 2A/1A receptors, suggesting that targeting serotonin 2A/1A 
receptors has implications for potential treatment of dysfunctional social cognition.
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Introduction
Empathy and moral behavior are fundamental components 
of human relationships and important for a well-functioning 
society (Decety and Cowell, 2014). They have been conceptually 
linked, and it is thought that empathy plays a crucial role in 
moral and prosocial behavior (Eisenberg, 2000). Both topics have 
undergone a renaissance in psychological and neuroscience 
research in the last decade (Christensen and Gomila, 2012; 
Decety and Cowell, 2014).
Empathy is a multidimensional construct consisting of at 
least a cognitive and an emotional component (Blair, 2005). 
Cognitive empathy describes the ability to adopt and under-
stand the mental or emotional state of another person without 
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necessarily sharing the emotional state. The term cognitive 
empathy can be used interchangeably with Theory of Mind or 
perspective taking (Blair, 2005). In contrast, emotional empathy 
is the ability to share the emotional state of another person. 
Empathy deficits have severe negative social effects such as 
social withdrawal as a result of experienced difficulties in recip-
rocal social interactions and communication (Baron-Cohen, 
2012). Impairments in empathic abilities are reported in various 
psychiatric disorders such as major depression disorder (Cusi 
et al., 2011; Fujino et al., 2014), bipolar disorder (Shamay-Tsoory 
et al., 2009), borderline personality disorder (Dziobek et al., 2011), 
and psychopathy (Blair, 2005). The clinical relevance of empa-
thy deficits is highlighted by evidence that a higher number of 
depressive episodes in major depression disorder patients is 
associated with a greater reduction in perspective-taking abili-
ties (Cusi et  al., 2011), suggesting that empathic abilities may 
become increasingly impaired with illness progression, which 
might contribute to a more severe course of depression.
Morality exerts a regulatory role in social decision-making 
and actions (Decety and Cowell, 2014). To investigate moral 
judgment and moral decision-making, cognitive neuroscience 
frequently uses moral dilemma tasks (Christensen and Gomila, 
2012). Moral dilemmas are commonly presented as short sto-
ries about a situation involving a moral conflict with 2 courses 
of action: utilitarian action and deontological action. Utilitarian 
action is the option that produces the highest welfare for the 
largest number of involved individuals. By contrast, deonto-
logical action is the option that respects the rights of persons 
and does not use persons as a means to an end. Moral dilem-
mas can be distinguished between personal moral and imper-
sonal moral dilemmas (Greene et al., 2001; Greene et al., 2004). 
Personal dilemmas are considered more emotionally engaging 
than impersonal dilemmas, because they contain a course of 
action where the individual directly implies serious bodily harm 
to a victim. People tend to rather choose deontological actions 
in personal moral dilemmas than in impersonal moral dilem-
mas (Greene et al., 2001). Utilitarian choices are seen as the fail-
ure to conform to the social norm to not harm others and are 
associated with antisocial behavior (Koenigs et al., 2007; Bartels 
and Pizarro, 2011). Increased utilitarian responses in personal 
moral dilemmas are found in adults with high-functioning 
autism (Gleichgerrcht et  al., 2013), low-anxious psychopaths 
(Koenigs et al., 2012), alcohol-dependent patients (Khemiri et al., 
2012), poly-substance patients (Carmona-Perera et al., 2012), and 
patients with lesions in prefrontal cortex (Ciaramelli et al., 2007; 
Koenigs et al., 2007).
To date, studies investigating the neuropharmacologi-
cal underpinnings of social experiences and behavior such as 
empathy and moral decision-making are scarce. Serotonin 
(5-hydroxytryptamine, 5-HT) seems to be crucially involved 
in both processes. Recent pharmacological studies in healthy 
human subjects showed that the 5-HT-releasing agent 3,4-meth-
ylenedioxymethamphetamine (MDMA) increased emotional 
empathy but did not affect cognitive empathy on the multifac-
eted empathy test (MET) (Hysek et al., 2014; Kuypers et al., 2014; 
Schmid et al., 2014). Given that pretreatment with the 5-HT1A 
antagonist pindolol did not attenuate the empathogenic effects 
of MDMA in the MET, it has been speculated that these effects 
might be mainly driven by 5-HT2A receptor activation (Kuypers 
et al., 2014). However, this hypothesis has not yet been tested. 
Furthermore, recent studies indicated that the 5-HT system 
is also involved in moral processes. Specifically, manipulating 
the serotonergic tone by the administration of a single dose of 
the serotonin reuptake inhibitor citalopram in healthy subjects 
increased subjects’ aversion to personally harm others in the 
judgment of personal moral dilemmas but did not affect imper-
sonal moral dilemmas (Crockett et al., 2010). Furthermore, cital-
opram also increased harm aversion for self and others in moral 
decision-making to inflict pain on oneself and others for finan-
cial gain (Crockett et al., 2015). Given the involvement of sero-
tonin in social processes and the need for improved and more 
tailored pharmacological treatments of social deficits in psychi-
atric disorders (Derntl and Habel, 2011), it is important to better 
understand the specific contribution of different 5-HT receptor 
subtypes to social experiences (e.g., empathy) and social behav-
ior (e.g., moral decision-making).
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a 
hallucinogen that produces dose-dependently an altered state 
of consciousness characterized by changes in sensory per-
ception, emotion, thought, and the sense of self (Hasler et al., 
2004; Studerus et al., 2011). Psilocybin binds to 5-HT1A, 5-HT1B, 
5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5, 5-HT6, and 5-HT7 
receptors (PDSP database https://pdspdb.unc.edu/pdspWeb/). In 
humans, psilocybin is rapidly dephosphorylated into the metab-
olite psilocin (4-N,N-dimethyltryptamine) (Hasler et al., 1997), 
which acts as a partial agonist at 5-HT2A and 5-HT1A receptors 
(Vollenweider et al., 1998; Halberstadt and Geyer, 2011). Human 
and animal studies showed reliably that the core psychological 
effects of psilocybin are primarily mediated via 5-HT2A receptor 
activation (Vollenweider et al., 1998; González-Maeso et al., 2007, 
2008; Halberstadt and Geyer, 2011). Specifically, the selective 
5-HT2A antagonist ketanserin blocked the psilocybin-induced 
subjective effects in a dose-dependent manner in humans 
(Vollenweider et al., 1998; Carter et al., 2007; Kometer et al., 2012). 
Moreover, accumulating evidence suggests that low to moder-
ate doses of psilocybin enhance positive mood and attenuate 
the processing of negative emotional and social stimuli such 
as threat-related scenes, negative facial expressions, and social 
rejection (Kometer et al., 2012; Schmidt et al., 2013; Bernasconi 
et al., 2014; Kraehenmann et al., 2014; Preller et al., 2016), mainly 
Significance Statement
Empathy is important for the maintenance of social relationships and plays a crucial role in moral and prosocial behavior. This 
study investigated the acute effect of the serotonergic hallucinogen psilocybin in healthy human subjects on different facets 
of empathy and moral decision-making. Psilocybin significantly increased explicit and implicit emotional empathy, compared 
with placebo, whereas it did not affect cognitive empathy nor moral decision-making. These findings provide first evidence that 
psilocybin has distinct effects on social cognition by enhancing emotional empathy but not moral behavior. As the psychologi-
cal effects of psilocybin are primary mediated by serotonin (5-HT) 2A receptor activation and partially modulated by 5-HT1A 
receptor modulations, our findings suggest the implication of these receptor subtypes in everyday social experience. Therefore, 
targeting 5-HT2A/1A receptors may have potential beneficial effects in the treatment of mood disorders or psychopathy, which 
are characterized by deficits in social skills and in particular in the ability to feel with other people.
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by 5-HT2A receptor activation (Kometer et al., 2012). For exam-
ple, psilocybin has been shown to decrease the recognition of 
negative facial expressions in the reading the mind in the eyes 
test, an effect that was abolished by ketanserin (Kometer et al., 
2012). In addition, psilocybin has also been shown to decrease 
aggressive behavior in rodents (Kostowski et al., 1972; Uyeno, 
1978), suggesting that psilocybin may increase the aversion to 
harm others. Given the role of serotonin in empathy and moral 
decision-making and of the 5-HT2A receptor system in the 
mechanism of action of psilocybin, we hypothesize that psilocy-
bin impairs cognitive empathy for negative stimuli as shown in 
the reading the mind in the eyes test, whereas it increases emo-
tional empathy. Further, we hypothesize that psilocybin reduces 
utilitarian choice of action in personal moral dilemmas.
Methods
Participants
Thirty-three healthy human subjects were recruited through 
advertisements placed at local universities. The MET was con-
ducted in 33 subjects. One participant did not understand the 
task and had to be excluded from the study; thus, data of 32 par-
ticipants (17 men, 15 women, mean age 26.72 ± 5.34 years, range 
20–38 years) were included in the data analysis. Due to technical 
reasons, the moral dilemma task (MDT) had been implemented 
at a later stage during the study and was conducted in 24 sub-
jects immediately after the MET; thus, 24 participants (13 men, 
11 women, mean age 26.63 ± 5.33 years; range, 20–38) completed 
both tasks.
Healthy subjects, aged between 20 and 40  years and will-
ing to refrain from consuming illicit psychoactive drugs from 
at least 2 weeks before the first experimental session until the 
last experimental session, were included in the study. All par-
ticipants underwent a physical examination including elec-
trocardiography and detailed blood and urine analyses (drug 
screening and pregnancy test) at a screening visit. Pregnant 
women were identified by urine tests and excluded. A  self-
report drug questionnaire was used to exclude subjects with a 
history of drug dependence. To exclude subjects with present or 
antecedent neurologic and psychiatric disorders or a history of 
major psychiatric disorders in first-degree relatives, we used the 
mini-international neuropsychiatric interview, a structured psy-
chiatric interview (Sheehan et al., 1998), the Structured Clinical 
Interview for DSM-IV Axis II Personality Disorders (First et al., 
1997), and the John Hopkins Symptom Checklist-90 revised 
(Derogatis and Unger, 2010). A total of 39 subjects were screened 
whereby 6 subjects did not meet the inclusion/exclusion criteria 
and therefore were excluded.
Before participating, all participants gave their written 
consent after having received detailed written and oral infor-
mation about the aims of the study and the effects and pos-
sible risks of psilocybin administration in accordance with the 
Declaration of Helsinki. The study was approved by the Ethics 
Committee of the Department of Public Health of the Canton 
of Zurich, Switzerland, and the use of psilocybin was author-
ized by the Swiss Federal Office for Public Health, Department of 
Pharmacology and Narcotics, Berne, Switzerland.
Study Design
This study was designed as a double-blind, randomized, placebo-
controlled, within-subject design with 2 experimental sessions. 
Each participant received psilocybin on one session (0.215 mg/
kg body weight, p.o.) and the same amount of identical-looking 
gelatine capsules containing placebo (mannitol) on the other 
session. The 2 sessions were separated by at least 10 days.
Study Procedures
Participants were requested to refrain from drinking alcohol 
the day before the experimental session as well as from drink-
ing alcohol and caffeinated beverages during the experimental 
days. The absence of acute drug use was assured by urine tests 
conducted before each experimental session. Participants com-
pleted the MET (Dziobek et al., 2008) and the MDT (Harrison et al., 
2012) on a computer in a quiet room 160 minutes after substance 
administration, when the peak perceptual/visual effect of psilo-
cybin had already markedly subsided (Hasler et al., 2004). The 
Altered States of Consciousness Rating Scale (5D-ASC) (Dittrich, 
1998) was used 360 minutes after drug intake when the drug 
effects have completely subsided to retrospectively quantify the 
acute subjective effect of psilocybin. The Positive and Negative 
Affect Schedule (PANAS) (Watson et al., 1988) was applied before 
and 360 minutes after drug intake to assess the acute effect of 
psilocybin on mood. Participants were monitored until the drug 
effects had completely worn off. This was assessed by a trained 
physician interviewing participants at the end of each session.
Measures
Interpersonal Reactivity Index
The Interpersonal Reactivity Index (IRI) (Davis, 1980, 1983) 
(German version: Paulus, 2009) is a self-report questionnaire to 
measure trait empathy and was applied at the screening visit. The 
short form contains 16 items with a 5-point Likert scale (1 = never; 
5 = always). The questionnaire assesses aspects of cognitive and 
affective empathy by means of 4 subscales: perspective taking (PT) 
and fantasy (FS) as cognitive empathy subscales, and empathic 
concern (EC) and personal distress (PD) as affective empathy sub-
scales. PT measures the tendency to adopt the psychological point 
of view of others, whereas FS measures the disposition to identify 
with fictional characters. EC captures the other-oriented tendency 
to experience feelings of compassion, and concern for others, 
whereas PD assesses self-oriented tendency to feel unease and 
discomfort resulting from the emotions of others.
MET
The MET is a PC-assisted test that assesses cognitive empathy as 
well as explicit and implicit emotional empathy (Dziobek et al., 
2008). It consists of 40 photorealistic stimuli showing people in 
different emotionally charged situations (20 positive, 20 nega-
tive). Each picture is presented 3 times with a different ques-
tion to assess the 3 different components of empathy. Cognitive 
empathy is operationalized by the question “What is this person 
feeling?” and participants have to identify the correct mental 
state from a list of 4 choices. Explicit emotional empathy is oper-
ationalized by the question “How concerned are you for this per-
son” (negative valence pictures) and “How happy are you for this 
person” (positive valence pictures) with a 9-point Likert scale 
(1 = not at all; 9 = very much), respectively. To allow for the meas-
urement of emotional empathy while reducing subjects’ ten-
dencies to give socially desirable answers, an implicit emotional 
empathy condition was also included, which is operationalized 
by the question “How calm/aroused does this picture make you 
feel?” with a 9-point Likert scale (1 = very calm; 9 = very aroused).
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MDT
For the MDT, 2 different sets of matched scenarios containing 
standard hypothetical moral dilemmas were constructed. They 
were matched according to previously reported emotional rat-
ings and ratio of utilitarian answers (Koenigs et al., 2007; Harrison 
et  al., 2012). Each set consists of 22 vignettes (adapted from 
Harrison et al., 2012), illustrating 9 personal dilemmas (thereof 
2 inevitable scenarios), 9 impersonal dilemmas, and 4 nonmoral 
dilemmas. Inevitable scenarios describe situations in which the 
hypothetical victim dies regardless of the participant’s interven-
tion. Nonmoral dilemmas are scenarios in which the participant 
chooses between an advantage and a disadvantage for himself 
without consequences for others. The vignettes were shown on a 
computer screen, while the dilemmas were presented auditorily 
via headphones. The participant was asked to take the perspec-
tive of a protagonist as all dilemmas are presented in a way that 
“you” are involved in these scenarios. At the end of each sce-
nario participants were asked to decide if they would choose a 
utilitarian (sacrifice one or more people to save a higher amount 
of people) or harm avoidance (no intervention) course of action.
5D-ASC
The 5D-ASC (Dittrich, 1998) was used to assess subjective drug 
effects in both experimental sessions. The 5D-ASC is a stand-
ardized questionnaire comprising 94 items to be answered on 
visual analogue scales and is an extension of the OAV (Bodmer 
et  al., 1994) containing 66 items. All items from the OAV are 
incorporated in the 5D-ASC, and the following validated 11 OAV 
scale scores (Studerus et al., 2010) were computed: experience 
of unity, spiritual experience, blissful state, insightfulness, dis-
embodiment, impaired control and cognition, anxiety, complex 
imagery, elementary imagery, audio-visual synesthesia, and 
changed meaning of percepts. The 5D-ASC scores are expressed 
as percentage scores of maximum scale values.
PANAS
The PANAS (Watson et  al., 1988) was used to assess the self-
reported positive and negative affect. Participants are asked 
to rate the extent to which they experience 20 emotions on a 
5-point Likert scale (1 = very slightly or not at all; 5 = extremely). 
The questionnaire contains 7 arousal-related items (Russell and 
Carroll, 1999): active, alert, attentive, excited, distressed, jittery, 
and upset. To measure drug-induced mood changes, the ques-
tionnaire was given before (pre) and 360 minutes (post) after 
drug intake.
Statistical Analysis
Data were analyzed using STATISTICA 8.0 for Windows (StatSoft). 
For the MET, repeated-measures ANOVAs were computed to 
analyze data of each empathy component (cognitive empathy, 
explicit emotional empathy, implicit emotional empathy) with 
drug (psilocybin, placebo) and valence (positive stimuli, nega-
tive stimuli) as within-subject factors and order (placebo first, 
psilocybin first) as between-subjects factor. For the MDT, the ratio 
of utilitarian choice (amount of utilitarian answers/total ques-
tions) for each category was computed, and a repeated-measures 
ANOVA was conducted to analyze the ratio of utilitarian choices 
with moral dilemma category (personal avoidable dilemma, per-
sonal inevitable dilemma, impersonal dilemma) and drug (psilo-
cybin, placebo) as within-subject factors and order (placebo first, 
psilocybin first) as between-subjects factor. To compare the ratio 
of correct answers in nonmoral dilemma scenarios between the 
placebo and psilocybin condition, a paired t test was conducted. 
To control for psilocybin-induced mood changes on the scores of 
the MET and MDT, ANCOVAs with changes scores (post minus pre 
psilocybin condition) of positive affect and negative affect from 
the PANAS as covariates were performed. Independent-samples 
t tests were performed between psilocybin-experienced (n = 10) 
and psilocybin-naïve (n = 22) participants to compare their MET 
and MDT scores in the psilocybin condition. A  repeated-meas-
ures ANOVA with drug (psilocybin, placebo) and 5D-ASC scale 
scores (experience of unity, spiritual experience, blissful state, 
insightfulness, disembodiment, impaired control and cognition, 
anxiety, complex imagery, elementary imagery, audio-visual syn-
esthesiae, changed meaning of percepts) as within-subject fac-
tors were computed for the 5D-ASC ratings. A repeated-measures 
ANOVA with drug (psilocybin, placebo), time (pre, post), and scale 
scores (positive affect, negative affect) as within-subject factors 
were computed for the PANAS scores. Tukey posthoc comparisons 
followed significant main effects or interactions in the ANOVAs. 
In case of significant drug effects on outcome measures, change 
scores were computed (psilocybin minus placebo). To test the 
potential role of increased arousal on significant outcome meas-
ures, an arousal change score (post minus pre drug administra-
tion) from the mean of the 7 arousal-related PANAS items (Russell 
and Carroll, 1999) was computed. A moderator analysis was con-
ducted to ascertain whether the relationship between changed 
meaning of percepts change scores and implicit emotional empa-
thy change scores is influenced by arousal. To represent the inter-
action between changed meaning of percepts and arousal, the 
variables were first centered and then multiplied together. PANAS 
scores of one subject could not be analyzed due to missing data. 
Finally, the potential effects of altered states of consciousness 
(5D-ASC scales change scores), mood change (PANAS post minus 
pre psilocybin condition), and trait empathy (IRI subscales) on sig-
nificant outcome measures were explored by means of multiple 
regression analyses using the backward stepwise method. The 
confirmatory statistical comparisons of all data were carried out 
on a significance level set at P < .05 (2-tailed).
RESULTS
IRI
Participants’ scores of the 4 IRI subscales are presented in 
Table 1.
5D-ASC
There was a significant drug x scale interaction (F(10,310) = 25.06, 
P < .0001), a significant main effect of scale (F(10,310) = 24.57; P < .0001) 
and a significant main effect of drug (F(1, 31)  = 100.66, P < .0001). 
Posthoc tests revealed that except for the anxiety score (P > .8), psilo-
cybin significantly increased all scale scores compared with placebo 
(all P < .0001, except for spiritual experience P < .05) (Figure 1a).
Table 1. Self-Reported Trait Empathy Scores of the Interpersonal Re-
activity Index (IRI) of 32 Subjects
IRI subscale Mean SD Min Max
Perspective taking (4–20) 15.19 2.18 9 19
Fantasy (4–20) 12.56 3.23 6 19
Empathic concern (4–20) 13.84 2.41 9 20
Personal distress (4–20) 08.69 2.58 5 15
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PANAS
There was a significant drug x time x scale interaction 
(F(1,30) = 6.58, P < .05), a significant drug x time interac-
tion (F(1,30) = 17.34, P < .001), and a significant main effect of 
scale (F(1,30) = 313.64, P < .0001), indicating that ratings on the 
positive affect scale were higher than on the negative affect 
scale. Posthoc tests revealed that positive affect ratings were sig-
nificantly increased under psilocybin (P < .05), but not negative 
affect ratings (P > .8), whereas placebo did not lead to significant 
changes in positive affect (P > .2) nor negative affect (P > .8) rat-
ings (Figure 1b). There was a significant difference in the change 
Figure 1. Psychological effects of psilocybin. (A) Scores of the Altered States of Consciousness Rating Scale (5D-ASC) scales (n = 32). Psilocybin significantly increased all 
scale scores compared with placebo (all P < .05), except for anxiety (P > .8). (B) Scores of the Positive and Negative Affect Schedule (PANAS) (n = 31). Mood states compared 
from pre to post (360 minutes after drug intake). Psilocybin significantly increased positive mood (P < .05) but not negative mood (P > .8), whereas placebo had no effects 
on the mood scales (all P > .2). Data are expressed as mean ± SEM. *P < .05, **P < .0001.
Downloaded from https://academic.oup.com/ijnp/article-abstract/20/9/747/3868840
by University of Zurich user
on 08 February 2018
752 | International Journal of Neuropsychopharmacology, 2017
of arousal level between placebo (M = -0.07; SD = 0.32) and psilo-
cybin (M = 0.25; SD = 0.39) conditions (t(31) = -3.96; P < .001).
MET
A significant main effect for drug (F(1,30) = 7.74, P < .01) revealed 
that psilocybin increased explicit emotional empathy compared 
with placebo (Figure 2a). The interaction drug x valence on explicit 
emotional empathy was not significant (F(1,30) = 2.97, P > .09). 
Neither the interaction drug x valence x order (F(1,30) = 1.98, 
P > .1) nor the interaction drug x order (F(1,30) = 3.83, P > .07) was 
significant. There was no significant main effect for valence 
(F(1,30) = 0.11, P > .7) or order (F(1,30) = 2.51, P > .1). For implicit emo-
tional empathy, a significant main effect for drug (F(1,30) =  4.77, 
Figure 2. Multifaceted empathy test (MET). (A) Psilocybin significantly increased the mean rating of explicit and implicit emotional empathy (each P < .01) compared 
with placebo regardless of the valence of the stimuli. (B) No significant effect of psilocybin on the mean of correct answers of cognitive empathy (P > .2) compared with 
placebo were found. In general, participants made significantly more mistakes for negative stimuli than positive stimuli (P < .05). Data are expressed as mean ± SEM 
in 32 subjects. *P < .05.
Downloaded from https://academic.oup.com/ijnp/article-abstract/20/9/747/3868840
by University of Zurich user
on 08 February 2018
Pokorny et al. | 753
P < .05) revealed that psilocybin increased implicit emotional 
empathy compared with placebo (Figure  2a). The interaction 
drug x valence was not significant (F(1,30) = 0.00, P > .9). Neither 
the interaction drug x valence x order (F(1,30) = 0.01, P > .9) nor 
the interaction drug x order (F(1,30) =  2.03, P > .1) was significant. 
There was no significant main effect for valence (F(1,30) = 1.05, 
P > .3), nor order (F(1,30) = 3.40, P > .07). There was no significant 
drug x valence x order interaction (F(1,31) = 0.51, P > .4) nor drug 
x valence interaction (F(1,30) = 0.84, P > .3) for cognitive empa-
thy and no significant main effect for drug (F(1,30) = 1.45, P > .2). 
There was a significant drug x order interaction (F(1,30) = 5.17, 
P < .05). Posthoc tests revealed that participants had slightly 
higher scores in their second test session compared with the 
first test session independently of drug condition and adminis-
tration order, as there were neither significant differences in the 
ratings between drug conditions, nor between administration 
order (all P > .08). A significant main effect for valence (F(1,30) = 
6.58, P < .05) revealed that participants made more mistakes 
on negative than positive stimuli independent of drug condi-
tion (Figure 2b). There was no significant main effect for order 
(F(1,30) = 0.01, P > .9). When adding positive or neg ative mood 
as a covariate in the analyses, all results remained the same, 
except for implicit emotional empathy when controlling for pos-
itive mood (F(1,30) = 2.62, P > .11). Further, independent-samples 
t tests revealed no significant differences for psilocybin-experi-
enced and psilocybin-naïve participants in the MET scores (all 
P > .05) in the psilocybin condition.
Associations between MET Change Scores and 
5D-ACS Change Scores, PANAS Change Score 
and IRI
Multiple linear regression analysis revealed that 5D-ASC scale 
scores explain a significant amount of the variance in the 
increase of implicit emotional empathy scores (F(1,31) = 11.23, 
P < .01, R2 = .27, R2Adjusted = .24). The analysis showed that only 
changed meaning of percepts scores significantly predict the 
increase of implicit emotional empathy scores (Beta = .52, 
t(31) = 3.35, P < .01). No significant results were obtained when the 
analysis was performed for explicit emotional empathy scores.
As the scale changed meaning of percepts and implicit emo-
tional empathy both contain questions regarding arousal, we 
tested if this  relationship was moderated by arousal as meas-
ured with the PANAS. Changed meaning of percepts change 
scores and arousal were entered in the first step of the regres-
sion analysis. The model explained a significant amount of the 
variance in the increase of implicit emotional empathy scores 
(F(2,29) = 5.31, P < .05, R2 = .27, R2Adjusted = .22). It was found that 
changed meaning of percepts (Beta = .47, t(29) = 2.60, P < .05) sig-
nificantly predicted the increase in implicit emotional empathy 
but not arousal (Beta = .09, t(29) = 0.47, P > .6). In the second step of 
the regression analysis, the interaction term between changed 
meaning of percepts and arousal was entered. This model 
explained a significant amount of the variance in the increase of 
implicit emotional empathy scores (F(3,28) = 4.18, P < .05, R2 = .31, 
R2Adjusted = .24). The analysis shows that only changed meaning 
of percepts scores significantly predict the increase of implicit 
emotional empathy scores (Beta = .47, t(28) = 2.64, P < .05), but nei-
ther arousal (Beta = .07, t(28) = 0.38, P > .7) nor the interaction term 
(Beta = .20, t(28) = 1.30, P > .2). Thus, arousal was not a significant 
moderator of the relationship between changed meaning of 
percepts and implicit emotional empathy. To investigate if IRI 
subscale scores or the change scores of the PANAS predict the 
increase in emotional empathy scores, separate multiple linear 
regression analyses for explicit and implicit emotional empathy 
were performed with IRI subscale scores and PANAS scores as 
predictors using the backward stepwise method. No significant 
models were obtained (all P > .05).
MDT
There was no significant drug x category interaction 
(F(2,44) = 0.97, P > .3). Neither the drug x category x order inter-
action (F(2,44) = 0.94, P > .4), nor the drug x order interaction 
(F(1,22) = 0.91, P > .3) was significant. There was no significant 
main effect for drug (F(1,22) = 0.37, P > .5), no significant main 
effect for order (F1,22) = 0.02, P > .8), and no significant main effect 
for category (F(2,44) = 2.77, P > .08) for moral dilemmas (Figure 3). 
In the nonmoral dilemma scenarios, there was a significant 
difference between the scores for placebo (M = 0.99; SD = 0.05) 
Figure 3. Mean ration of utilitarian choices in 3 different moral dilemma categories from the moral dilemma task (MDT). No effects of psilocybin on moral dilemmas 
were found. Categories: personal moral avoidable (PM AV); personal moral inevitable (PM IN); impersonal moral (IPM). Data are expressed as mean ± SEM in 24 subjects.
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and psilocybin (M = 0.91; SD = 0.16) condition; t(23) = 2.98, P < .01), 
revealing that participants gave more incorrect answers in the 
psilocybin condition. When adding positive or negative mood 
as a covariate in the analyses, all results remained the same. 
Further, independent-samples t tests revealed no significant dif-
ferences for psilocybin-experienced and psilocybin-naïve par-
ticipants in the MDT scores (all P > .1) in the psilocybin condition.
Discussion
Psilocybin significantly increased explicit and implicit emo-
tional empathy independent of stimuli valence. The increase in 
implicit emotional empathy was related to alterations in mean-
ing of percepts but not trait empathy. There was no significant 
change in cognitive empathy between placebo and psilocybin. 
Although psilocybin led to an increase of emotional empathy, no 
significant difference in decision-making on hypothetical moral 
dilemmas was found between placebo and psilocybin.
The present finding suggests that 5-HT2A and 5-HT1A 
receptor systems may be important in the experience of emo-
tional empathy regardless of the emotional valence of the 
stimuli. Interestingly, previous work has shown that psilocybin 
modulates the processing and recognition of negative social 
and nonsocial stimuli, presumably via 5-HT2A and/or 5-HT1A 
receptor activation (Kometer et al., 2012; Schmidt et al., 2013; 
Bernasconi et al., 2014; Kraehenmann et al., 2014; Preller et al., 
2016). Specifically, it has been shown that activation of 5-HT2A 
receptors is implicated in early encoding and recognition of 
negative facial expressions (Kometer et al., 2012; Schmidt et al., 
2013), whereas the 5-HT1A receptor activation seems to influ-
ence later processing of both negative and positive facial expres-
sion (Kometer et al., 2012; Schmidt et al., 2013; Bernasconi et 
al., 2014, 2015). Taken together, the present results extend these 
findings and suggest that the 5-HT2A receptor and possibly also 
the 5-HT1A receptor are not only implicated in the processing of 
social and nonsocial emotional stimuli but that they may also 
be involved in sharing the emotional state of another person 
(implicit emotional empathy) and the experience of sympa-
thy and prosocial attitudes towards others (explicit emotional 
empathy). Furthermore, cognitive empathy remained unaf-
fected by psilocybin, indicating that participants completed the 
task attentively and correctly. In contrast to emotional empathy, 
which measures one’s current experience of the emotional state 
of another person, cognitive empathy/Theory of Mind requires 
the ability to correctly identify the other person’s emotions. 
It is possible that emotional empathy in contrast to cognitive 
empathy is dependent on state variables and may therefore be 
manipulated more easily whereas it probably takes more time to 
acquire new cognitive empathy skills.
The 5D-ASC scale score changed meaning of percepts 
assesses a change in the significance of objects or the sur-
roundings and significantly predicted the increase in implicit 
emotional empathy scores in the psilocybin condition. Some 
items of this 5D-ASC scale also refer to a change in the rela-
tionship between the observer and the observed objects or the 
environment. This is reflected for example by the item “Objects 
around me engaged me emotionally much more than usual”. 
Such an increased emotional engagement seems to be reflected 
in the boosted implicit emotional empathy ratings in the pre-
sent study, indicating that the increased sense of significance 
may not solely refer to surrounding objects but also to the emo-
tional state of other persons. Although psilocybin significantly 
increased participant’s arousal scores on the PANAS, the rela-
tionship between implicit emotional empathy and changed 
meaning of percepts was not moderated by arousal. It is note-
worthy that the acute mood enhancing effects of psilocybin did 
not significantly predict the increase in emotional empathy. 
However, as there was no significant drug effect on implicit 
emotional empathy when controlling for psilocybin-induced 
positive affect, we cannot rule out that positive mood was asso-
ciated with increases in implicit emotional empathy. The psil-
ocybin-induced enhancement of emotional empathy was also 
not significantly predicted by the trait empathy score of the IRI 
questionnaire, suggesting that the acute empathy enhancing 
effect of psilocybin may build up independently from the sub-
ject’s baseline or trait empathy level. While the IRI scores in our 
study sample are comparable with scores from a meta-analysis 
investigating US college students from 1980 to 2009 (Konrath et 
al., 2011), the finding that psilocybin’s empathy enhancing effect 
is independent from trait empathy might be especially relevant 
for the treatment of psychiatric disorders where the affected 
patient has low trait empathy levels such as in psychopathy 
(Blair, 2005). In line with this idea studies in the 1960s suggested 
that psychedelics such as psilocybin and LSD might be useful in 
the treatment of psychopaths and criminals (Tenenbaum, 1961; 
Arendsen-Hein, 1963; Leary and Metzner, 1968). Finally it is note-
worthy that the implicit and explicit emotional empathy ratings 
were not associated with the psilocybin-induced visual illusions 
and hallucinations suggesting that the empathy enhancement 
is not simply based on visual inaccuracy or disturbances.
A recent fMRI study using the MET showed that emotional 
empathy in healthy subjects is associated with increased 
BOLD responses in the brainstem, inferior frontal cortex, pos-
terior superior temporal sulcus, temporal lobe, posterior insu-
lar cortex, and posterior cingulate cortex (Dziobek et al., 2011). 
Whereas prefrontal areas seem to be specifically related to sim-
ulating the perspective of others and stepping into their shoes 
(Mitchell, 2009), regions such as the insula and amygdala appear 
to be important for enabling the experience of emotional empa-
thy (Blair, 2005; Singer and Lamm, 2009; Dziobek et  al., 2011). 
Given that psilocybin increased neuronal activity as indexed 
by cerebral glucose metabolism or cerebral blood flow in fron-
tomedial and frontolateral cortices including the anterior cin-
gulate cortex (ACC), the temporomedial cortex, the insula, and 
the basal ganglia (Vollenweider et al., 1997; Gouzoulis-Mayfrank 
et al., 1999; Geyer and Vollenweider, 2008) it is conceivable that 
psilocybin may increase emotional empathy via activation of 
frontal-temporal and subcortical structures.
The present findings on the effects of psilocybin in the 
MET endorse the importance of the 5-HT system in empathy. 
Similar effects were found in previous studies investigating 
the influence of the 5-HT releasing agent MDMA on the same 
task (Hysek et  al., 2014; Kuypers et  al., 2014; Schmid et  al., 
2014). Specifically, MDMA significantly increased explicit and 
implicit emotional empathy for all stimuli (Hysek et al., 2014). It 
is noteworthy that neither oxytocin nor pretreatment with the 
5-HT1A receptor antagonist pindolol modulated the empatho-
genic effects of MDMA (Kuypers et al., 2014). Moreover, a recent 
study showed that LSD, which acts as an agonist at multiple 
5-HT and dopamine receptor sites (Passie et  al., 2008), dose-
dependently increased explicit and implicit emotional empathy, 
but in contrast to the present findings with psilocybin, LSD in 
addition impaired cognitive empathy (Dolder et al., 2016). As the 
psychological effects of psilocybin are primarily mediated via 
5-HT2A receptor activation and partially modulated by 5-HT1A 
receptor manipulations (Vollenweider et al., 1998; Carter et al., 
2007; Kometer et al., 2012; Pokorny et al., 2016), both these 5-HT 
receptor sites may be crucially implicated in the generation of 
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emotional empathy. However, given that psilocybin acts also on 
other 5-HT receptor subtypes, further psilocybin studies in com-
bination with selective 5-HT receptor antagonists are warranted 
to examine the relative contribution of specific 5-HT recep-
tor subtypes on empathy. Although psilocybin also has down-
stream effects on the dopamine system (Vollenweider et  al., 
1998; Vollenweider et al., 1999; Halberstadt and Geyer, 2011), an 
involvement of the dopamine system in the current results is 
unlikely since administration of the dopamine reuptake inhibi-
tor methylphenidate did not lead to increased empathy ratings 
in the MET (Schmid et al., 2014).
Whereas psilocybin increased emotional empathy, it did not 
affect moral decision-making in any dilemma condition in the 
MDT. Neuroimaging studies revealed that moral decision-mak-
ing and empathy are mediated by overlapping networks (Greene 
et al., 2001; Moll et al., 2002; Greene et al., 2004; Eslinger et al., 
2009; Decety et  al., 2012), but they also have distinct neuronal 
correlates (Bzdok et al., 2012). Our finding is well in line with the 
observation that the serotonin-releasing agent MDMA increased 
emotional empathy but had no effects on moral judgment 
in moral dilemma tasks (Schmid et al., 2014). Further, a meta-
analysis of fMRI and PET studies investigating the relationship 
between morality and empathy revealed that affective sharing 
is unlikely involved during moral decisions (Bzdok et al., 2012). 
However, our finding is somewhat surprising given that manip-
ulating the serotonergic tone by a single dose of the serotonin 
reuptake inhibitor citalopram was reported to lead to harm 
avoidance in the judgment of personal moral dilemmas (Crockett 
et  al., 2010) and to an aversion for painful electric shocks for 
oneself and others (Crockett et  al., 2015). However this appar-
ent discrepancy may be explained by the fact that Crockett et al. 
(2010) had examined moral judgments (“Is it acceptable to…?”), 
whereas we investigated moral decision-making with a choice of 
action (“Would you…?”) condition. A recent study investigating 
whether evaluative judgments and choices of action differ when 
people make decisions on dilemmas involving moral issues sug-
gests that judgment and choice of action are mediated, at least 
in part, by distinct psychological processes (Tassy et  al., 2013), 
which in turn rely on different neural underpinnings (Tassy et al., 
2012). Specifically, using identical dilemma tasks it has been sug-
gested that moral judgment is linked to the functional integrity 
of the right dorsolateral prefrontal cortex, whereas moral action 
choice may mainly rely on ventromedial prefrontal cortex func-
tion (Cima et al., 2010; Tassy et al., 2012). Taken together, these 
findings and the dissociable effects of psilocybin on empathy 
and choice of action suggest that the 5-HT2A/1A receptor system 
may not be involved in moral decision-making. However, it may 
also be possible that higher doses of psilocybin are needed to 
alter the functional integrity of the neuronal networks underly-
ing social moral decisions and choices of action.
Furthermore, it is also noteworthy that personal moral sce-
narios involve emotionally salient violent acts. Such scenarios 
activate brain regions implicated in emotional processing, 
including visual pathways and the amygdala (Greene et  al., 
2001, 2004). Psilocybin has been shown to reduce the neuronal 
response to social exclusion in the ACC (Preller et al., 2016) and 
to lead to a decreased amygdala reactivity to threatening stimuli 
(Kraehenmann et al., 2014). Thus, it is possible that emotionally 
loaded personal moral scenarios were less emotionally salient 
in the psilocybin condition and therefore psilocybin did not 
enhance aversive emotional reactions to harm others as it was 
found with citalopram (Crockett et al., 2010).
Although participants made significantly more errors in 
nonmoral dilemmas under psilocybin than under placebo, the 
error rate in the psilocybin condition (9%) remained very low 
as well. We are therefore confident that participants could com-
plete the task after psilocybin administration. However, we can-
not rule out that this increase could be due to tiredness, as the 
task was run as the last test of the session. Therefore, it is possi-
ble that deficits in attention may have masked potential effects 
in the MDT.
In conclusion, whereas moral decision-making was unaf-
fected by psilocybin, the results from the MET indicate that 
psilocybin enhances emotional empathy but not the cognitive 
component of empathy. This finding highlights the possible role 
of 5-HT2A/1A receptors in everyday social experience. Therefore, 
5-HT2A/1A receptor agonists may have potential beneficial 
effects in the treatment of mood disorders or psychopathy, 
which are characterized by deficits in social skills and in par-
ticular in the ability to feel with other people.
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